143 related articles for article (PubMed ID: 3437623)
41. GnRH receptors in human breast cancer and its contiguous not-involved breast tissue.
Paradiso A; Pezzetta A; Cellamare G; Schittulli F; Marzullo F; Reshkin SJ
J Endocrinol Invest; 2000 Feb; 23(2):90-6. PubMed ID: 10800761
[TBL] [Abstract][Full Text] [Related]
42. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy.
Manni A; Arafah B; Pearson OH
Cancer; 1980 Dec; 46(12 Suppl):2838-41. PubMed ID: 7448730
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
[TBL] [Abstract][Full Text] [Related]
44. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
Alexieva-Figusch J; Van Putten WL; Blankenstein MA; Blonk-Van Der Wijst J; Klijn JG
Cancer; 1988 Feb; 61(4):758-68. PubMed ID: 3338038
[TBL] [Abstract][Full Text] [Related]
45. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.
Namer M; Lalanne C; Baulieu EE
Cancer Res; 1980 May; 40(5):1750-2. PubMed ID: 7371003
[TBL] [Abstract][Full Text] [Related]
46. Recombinant human interferon-alpha 2a increases hormone receptor level of a human breast carcinoma xenograft in nude mice and enhances the anti-proliferative activity of tamoxifen.
Josui K; Kubota T; Kitajima M
Jpn J Cancer Res; 1992 Dec; 83(12):1347-53. PubMed ID: 1483948
[TBL] [Abstract][Full Text] [Related]
47. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
48. Influence of estrogen structure on nuclear binding and progesterone receptor induction by the receptor complex.
VanderKuur JA; Wiese T; Brooks SC
Biochemistry; 1993 Jul; 32(27):7002-8. PubMed ID: 8334129
[TBL] [Abstract][Full Text] [Related]
49. [Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method].
Kurebayashi J; Horiuchi R; Nakamura T; Iino Y; Ishida T; Takigawa H; Izuo M
Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1351-63. PubMed ID: 2965035
[TBL] [Abstract][Full Text] [Related]
50. Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels.
Di Fronzo G; Coradini D; Cappelletti V; Miodini P; Granata G; Schwartz M; Panko WB
Anticancer Res; 1990; 10(6):1699-705. PubMed ID: 2285244
[TBL] [Abstract][Full Text] [Related]
51. Use of an enzymeimmunoassay (EIA) for quantitation of cytosolic and nuclear estrogen receptor, and correlation with progesterone receptor in human breast cancer.
Mobbs BG; Johnson IE
J Steroid Biochem; 1987 Dec; 28(6):653-62. PubMed ID: 3320574
[TBL] [Abstract][Full Text] [Related]
52. Use of serial semithin frozen sections to evaluate the co-localization of estrogen receptors and progesterone receptors in cells of breast cancer tissues.
Kudo A; Fukushima H; Kawakami H; Matsuda M; Goya T; Hirano H
J Histochem Cytochem; 1996 Jun; 44(6):615-20. PubMed ID: 8666746
[TBL] [Abstract][Full Text] [Related]
53. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
[TBL] [Abstract][Full Text] [Related]
54. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis MM; Robinson SP; Satyaswaroop PG; Jordan VC
Cancer Res; 1988 Feb; 48(4):812-5. PubMed ID: 3338079
[TBL] [Abstract][Full Text] [Related]
55. Oestrogen and progesterone receptors and response to endocrine therapy in Japanese breast cancer.
Nomura Y; Takatani O; Sugano H; Matsumoto K
J Steroid Biochem; 1980 May; 13(5):565-6. PubMed ID: 7392632
[TBL] [Abstract][Full Text] [Related]
56. Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines.
Trošt N; Hevir N; Rižner TL; Debeljak N
Int J Mol Med; 2013 Mar; 31(3):717-25. PubMed ID: 23314808
[TBL] [Abstract][Full Text] [Related]
57. Molecular aspects of estrogen receptor variants in breast cancer.
Fuqua SA; Wolf DM
Breast Cancer Res Treat; 1995 Sep; 35(3):233-41. PubMed ID: 7579493
[TBL] [Abstract][Full Text] [Related]
58. Simultaneous estimation of epidermal growth factor receptors and steroid receptors in a series of 136 resectable primary breast tumors.
Cappelletti V; Brivio M; Miodini P; Granata G; Coradini D; Di Fronzo G
Tumour Biol; 1988; 9(4):200-11. PubMed ID: 3420376
[TBL] [Abstract][Full Text] [Related]
59. Estradiol and progesterone binding in uterine leiomyomata and pregnant myometrium.
Nardelli GB; Mega M; Bertasi M; Siliotti F
Clin Exp Obstet Gynecol; 1987; 14(3-4):155-60. PubMed ID: 3454723
[TBL] [Abstract][Full Text] [Related]
60. Progesterone receptor activity and the response to the first endocrine therapy in advanced breast cancer.
Raemaekers JM; Beex LV; Pieters GF; Smals AG; Benraad TJ; Kloppenborg PW
Eur J Cancer Clin Oncol; 1987 Apr; 23(4):443-8. PubMed ID: 3609109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
